All In Biotech

Drug Trial Radar · NCT03406832

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Prevention of Coronary Slow Flow or No-Reflow During Elective Percutaneous Coronary Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction

Last checked: Nov 20, 2026Latest source record: Jun 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jan 8, 2018

Primary completion

Jun 30, 2019

Study completion Dec 31, 2019

Sponsor

Lead sponsor
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Anyang Regional Hospital; Huaihe Hospital of Henan University; The First Affiliated Hospital of Henan University of Science and Technology; Yellow River Sanmenxia hospital; The Peoples' Hospital of Jiaozuo City; Jincheng People's Hospital; The second people's Hospital of Jiyuan; Kaifeng Central Hospital; Lushan People's Hospital; Nanyang Central Hospital; The Second People's Hospital of Pingdingshan; Shenma Medical Group General Hospital; Puyang People's Hospital; Puyang Oilfield General Hospital; The First People's Hospital of Shangqiu; Yanshi People's Hospital; The First People's Hospital of Xinmi; First Affiliated Hospital of Xinjiang Medical University; Xinyang Central Hospital; People's Hospital of Zhengzhou University; Zhengzhou First People's Hospital; Chinese Academy of Medical Sciences, Fuwai Hospital; Zhengzhou Central Hospital; The 99th Central Hospital of the People's Liberation Army; Zhoukou Central Hospital; The First People's Hospital of Zhumadian; Zhumadian Central Hospital
First posted
Jan 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Elective percutaneous coronary intervention (EPCI) is the common treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following EPCI in STEMI patients has been a serious and common complication that closely related to the incidence of major adverse cardiovascular events (MACE) and affected patients' prognosis. No reflow is a multi-factorial phenomenon. And its preventive and therapeutic effects are not satisfactory. This prospective randomized controlled study aimed to compare favorable effects of Nitroprusside versus Tirofiban on the prevention of slow flow / no-reflow phenomenon during EPCI.

Conditions

  • ST Segment Elevation Myocardial Infarction
  • Elective Percutaneous Coronary Intervention

Interventions

  • Nitroprusside SodiumDrug

    Intracoronary infusion 50\~100μg each time (repeated)

  • Tirofiban HydrochlorideDrug

    Intracoronary infusion 10μg/kg for single time

  • Heparinized salineDrug

    Intracoronary infusion 2ml for single time

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Coronary artery flow using thrombolysis in myocardial infarction (TIMI) flow gradeTime frame: 1 minute after stent implantation; 1 minute after balloon dilatation
  2. Coronary TIMI frame countTime frame: 1 minute after stent implantation; 1 minute after balloon dilatation
  3. Slow flow / no-reflow phenomenonTime frame: 1 minute after stent implantation; 1 minute after balloon dilatation

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Anyang District Hospital

    Anyang, Henan, China · Recruiting

  • The 99th Central Hospital of the People's Liberation Army

    Jiaozuo, Henan, China · Recruiting

  • The People's Hospital of Jiaozuo

    Jiaozuo, Henan, China · Recruiting

  • The second people's Hospital of Jiyuan

    Jiyuan, Henan, China · Recruiting

  • Huaihe Hospital of Henan University

    Kaifeng, Henan, China · Recruiting

  • Kaifeng Central Hospital

    Kaifeng, Henan, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • Lushan People's Hospital

    Lushan, Henan, China · Recruiting

  • Nanyang City Center Hospital

    Nanyang, Henan, China · Recruiting

  • Pingmei Shenma Medical Group General Hospital

    Pingdingshan, Henan, China · Recruiting

  • The Second People's Hospital of Pingdingshan

    Pingdingshan, Henan, China · Recruiting

  • Puyang Oilfield General Hospital

    Puyang, Henan, China · Recruiting

  • Puyang People's Hospital

    Puyang, Henan, China · Recruiting

  • Yellow River Sanmenxia hospital

    Sanmenxia, Henan, China · Recruiting

  • The First People's Hospital of Shangqiu

    Shangqiu, Henan, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Recruiting

  • Xinyang Central Hospital

    Xinyang, Henan, China · Recruiting

  • Yanshi People's Hospital

    Yanshi, Henan, China · Recruiting

  • Zhengzhou First People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • Zhengzhou Cardiovascular Hospital

    Zhengzhou, Henan, China · Recruiting

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • People's Hospital of Zhengzhou

    Zhengzhou, Henan, China · Recruiting

  • The First People's Hospital of Xinmi

    Zhengzhou, Henan, China · Recruiting

  • Zhoukou Central Hospital

    Zhoukou, Henan, China · Recruiting

  • The First People's Hospital of Zhumadian

    Zhumadian, Henan, China · Recruiting

  • Zhumadian Central Hospital

    Zhumadian, Henan, China · Recruiting

  • Jincheng People's Hospital

    Jincheng, Shanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.